Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (51-60 of 181) with videos related to

Pageof 19
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 2, 2023
Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIVRaúl Rigo-Bonnin, Laura García-Tejada, Virgínia Mas-Bosch, et al.
HIV Clinical Trials|February 6, 2010
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppressionJosé R Santos, Josep M Llibre, Elena Ferrer, et al.
AIDS Research and Human Retroviruses|June 3, 2016
Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical PracticeMaria Saumoy, Josep M Llibre, Alberto Terrón, et al.
The Journal of Infectious Diseases|December 1, 2019
Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)Juan Tiraboschi, Arkaitz Imaz, Saye Khoo, et al.
AIDS (London, England)|July 29, 2004
Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcomaLuz Martin-Carbonero, Ana Barrios, Pere Saballs, et al.
Antiviral Therapy|January 25, 2014
Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/mlArkaitz Imaz, Josep M Llibre, Jordi Navarro, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 22, 2020
Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MSRaúl Rigo-Bonnin, Juan Manuel Tiraboschi, Marta Álvarez-Álvarez, et al.
AIDS (London, England)|December 14, 2019
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patientsChloe Orkin, Joseph J Eron, Jürgen Rockstroh, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|September 10, 2002
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinationsMarina Núńez, Carmen de Mendoza, Luisa Valer, et al.
Antiviral Therapy|December 15, 2015
Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once dailyJuan M Tiraboschi, Hernando Knobel, Arkaitz Imaz, et al.
Pageof 19

Showing results (51-60 of 181) with videos related to

Sort By:
Pageof 19
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 2, 2023
Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIVRaúl Rigo-Bonnin, Laura García-Tejada, Virgínia Mas-Bosch, et al.
HIV Clinical Trials|February 6, 2010
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppressionJosé R Santos, Josep M Llibre, Elena Ferrer, et al.
AIDS Research and Human Retroviruses|June 3, 2016
Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical PracticeMaria Saumoy, Josep M Llibre, Alberto Terrón, et al.
The Journal of Infectious Diseases|December 1, 2019
Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)Juan Tiraboschi, Arkaitz Imaz, Saye Khoo, et al.
AIDS (London, England)|July 29, 2004
Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcomaLuz Martin-Carbonero, Ana Barrios, Pere Saballs, et al.
Antiviral Therapy|January 25, 2014
Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/mlArkaitz Imaz, Josep M Llibre, Jordi Navarro, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 22, 2020
Measurement of total and unbound bictegravir concentrations in plasma and cerebrospinal fluid by UHPLC-MS/MSRaúl Rigo-Bonnin, Juan Manuel Tiraboschi, Marta Álvarez-Álvarez, et al.
AIDS (London, England)|December 14, 2019
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patientsChloe Orkin, Joseph J Eron, Jürgen Rockstroh, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|September 10, 2002
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinationsMarina Núńez, Carmen de Mendoza, Luisa Valer, et al.
Antiviral Therapy|December 15, 2015
Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once dailyJuan M Tiraboschi, Hernando Knobel, Arkaitz Imaz, et al.
Pageof 19